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1. Introduction 
Clinical research has identified blood transfusion as an independent risk factor for 
immediate and long-term adverse outcomes, including an increased risk of death, 
myocardial infarction, stroke, renal failure, infection and malignancy (Rawn, 2008). 
Blood transfusion is however widely used in orthopedic surgery although the performed 
surgery is mostly elective. Since the surgeries can, in the majority of cases, be planned ahead 
it is possible to reduce the use of blood and blood products by planning their use as well. 
In the past few years substantial steps have been taken to reduce the need for blood 
transfusion. The reduction of blood transfusion can be accomplished by several methods, 
the most successful of which seems to be a combination of different methods available. (van 
Erve, 2008). It is best to speak of blood management, which is the philosophy to improve 
patient outcomes by integrating all available techniques to reduce or eliminate allogeneic 
blood transfusions (Seeber & Shander, 2007). It should be a patient-centered, 
multidisciplinary, multimodal, planned approach to patient care (Seeber & Shander, 2007). 
In order to reduce the use of blood in orthopedic surgery the following separate steps can be 
identified. First the patients can be optimized before surgery. Second, the use of blood 
conserving techniques during surgery is to be applied. These steps are considered as 
Anaemia and Hemostasis Management. Third, the transfusion triggers can be set as low as 
possible (Appropriate transfusion practices). Finally, the use of re-transfusion of drainage 
fluids from the surgical wound can be used (Blood conservation). All these measures should 
improve patient outcomes. Figure 1 illustrates the interconnection of the different parts of 
blood management. 
In orthopedic surgery the above steps are relatively easy to carry out for there is sufficient 
time to organize them around the individual patient. 
We will discuss all possible measures to be taken to reduce the use of allogeneic blood in 
orthopedic surgery. 
2. Autologous transfusion 
Patients can be encouraged to donate their own blood prior to surgery (pre-donation). The 
use of this technique is limited to surgery that can be planned ahead as it needs adequate 
planning and time to restore the hemoglobin level while the blood should not be taken too 
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Fig. 1. Organogram as proposed by the Society for the Advancement of Blood Management 
(SABM) 
early in order to have adequate red cell quality. The storage time of the patient’s own red 
cells is the same as for allogeneic transfusions. Pre-donation should be done no more than 40 
days before surgery because the storage time of red cells is limited and known to be of 
utmost importance to the quality of the cells. As most of the surgery done in orthopedics is 
elective, especially in adult reconstruction, this technique is highly suitable. In trauma 
surgery this technique is less feasible because of the lack of time to schedule it and the acute 
need for blood in most major trauma. In trauma surgery other techniques should be used to 
avoid the use of allogeneic blood. We will discuss these techniques later in this chapter.  
Although pre-donated blood is safer than allogeneic blood it is not risk free and besides it is 
expensive (Domen, 1996). According to Domen the costs per saved quality adjusted life year 
may be as high as 1 million dollars. Vamvakas and Pineda found the cost effectiveness of 
pre-donation to be between 2,470 and 3,400,000 dollars per quality adjusted life year saved. 
The costs of predonation are high because the needs for collection, storage and avoidance of 
transfusion errors are expensive as well (Vamvakas & Pineda, 2000).  
A specialized organization for the use of autologous blood is imperative for the blood has to 
be specially assigned to every patient individually. For each patient to be assigned his/her 
own blood an extensive security system is required to reduce the risk of interchanging  
blood between patients. This makes such a practice expensive. In order to avoid transfusion 
errors the safety measures for this type of autologous donation have to be the same as for 
allogeneic transfusion. Its use is therefore limited to hospitals with their own blood banks 
guaranteeing the safety of the blood harvested from the patients and used for their own re-
transfusion when needed.  
As the donated blood is not extensively tested for transferable diseases, nor typed and 
screened, the blood harvested from one patient cannot be used for other patients. Domen 
found in 1996 that only half of the autologous units collected are actually used. The amount 
actually needed might even be smaller because physicians in attendance may judge it a 
waste of good blood not to return the donated blood to the patient, thus giving more 
transfusions than strictly necessary using restrictive transfusion triggers (Domen, 1996).  
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Pre-donation includes the risks associated with blood donation in general. In fact all the 
signs of anemia can occur, dependent on the amount of blood donated and thus on the 
extent of the surgery planned. The pre-donation procedure introduces an acute iron 
deficiency anemia with all possible sign and symptoms. Especially in the elderly population, 
which in orthopedic surgery is the main target group, symptoms may occur. The expected 
symptoms are fatigue, headaches, faintness, breathlessness, angina, intermittent 
claudication and palpitations. The claudication will occur in a relative high percentage of 
the population for many of the orthopedic patients have vascular problems too. Because the 
pre-donation introduces an iron deficiency anemia it is to be accompanied by iron infusions 
or erythropoetin to enhance the production of erythrocytes in order to have the hemoglobin 
and the hematocrit at an appropriate level before surgery. 
3. Pre-operative medication 
The percentage of patients for major elective orthopedic surgery presenting with marked 
anemia is 10.5%, using the World Health Organisation (WHO) criteria (Bisbe et al., 2008), 
while Bierbaum et al found up to 35% hemoglobin levels of 13g/dl or less in patients in the 
USA (Bierbaum et al., 1999). According to several studies (Goodnough et al., 2011), the 
postoperative mortality and morbidity increase while the postoperative functional recovery 
and the quality of life is impaired in the presence of a preoperative anemia (Beattie et al., 
2009; Conlon et al., 2008; Gruson et al., 2002). 
Preoperative medication can be prescribed to enhance the amount of erythrocytes in the 
circulation. This can be combined with the previously described pre-donation but can be 
used separately as well. The trigger for the use of preoperative medication is set to 13.2 g/dl 
or lower (Goldberg MA et al., 1996). This threshold has to be taken into account to avoid 
introducing the risk of polycythaemia. If polycytaemia is introduced the risk for thrombosis, 
haemorrhage and cardiac failure increases. Although the increase of thrombotic or other 
complications has never been proven (De Andrade et al., 1996; Faris et al., 1996), the risk for 
thrombosis in orthopedic surgery is high enough without it being increased by medication, 
especially in  hip and knee reconstructive surgery. 
Mainly two types of drugs are used; iron and erythropoietin. We will describe these 
medications below. 
3.1 Iron  
Intravenous iron can be used to boost the production of erythrocytes and is a component of 
autotransfusion practice. Especially in pre-donation it is extensively used. It is relatively safe 
and cheap medication though patients have to be admitted to hospital for the intravenous 
application. The adverse drug events have been studied by Johnson-Wimbley & Graham 
and Chertow et al. Some of the additional reported adverse events associated with iron 
preparations in their studies were hypotension, arthralgias, myalgias, malaise, abdominal 
pain, nausea, and vomiting. These non life-threatening adverse reactions were more 
commonly associated with iron dextran and less so with iron sucrose or sodium ferric 
gluconate (50%, 36%, 35%, respectively) (Johnson-Wimbley & Graham, 2011). The absolute 
rates of life-threatening adverse drug events were 0.6, 0.9, 3.3 and 11.3 per million for iron 
sucrose, sodium ferric gluconate complex, lower molecular weight iron dextran and higher 
molecular weight iron dextran, respectively (Chertow et al., 2006). 
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In an elaborate review Chritchley & Yenal found adverse events to be rare with slightly 
higher numbers in high molecular weight iron dextran than in low molecular weight iron 
dextran (Critchley & Yenal, 2007). 
The use of oral iron and of intravenous iron is being intensely studied at the moment. The 
Society for the Advancement of Blood Management publishes weekly articles of interest in 
his field at its website (www.SABM.org) 
The efficacy of preoperative iron supplementation is mounting. A study of 569 patients 
undergoing colorectal cancer surgery found that among the 116 patients who were anemic, 
intraoperative transfusion was needed in a significantly lower proportion of those who 
received 2 weeks of preoperative oral iron supplementation (200 mg) compared with those 
who received no iron therapy (9.4% vs 27.4%; P < .05) (Okuyama et al, 2005).  
According to Serrano-Trenas et al. intra-operatively iron infusion can be administered as 
successfully as preoperative iron infusions. They compared iron sucrose in hip fracture 
patients with no iron suppletion and found reduced transfusion requirements in patients with 
intra-capsular fractures and in those with hemoglobin levels of 12g/dl or more if given 600 mg 
intravenous iron during the operation (Serrano-Trenas et al., 2011),. They found no difference 
in mortality, morbidity or length of hospital stay, however (Serrano-Trenas et al., 2011). 
3.2 Erythropoietin 
Erythopoietin (EPO) is a glycoprotein hormone normally produced in the kidney. The 
renocortical interstitial cells secrete it in response to reduced oxygen tension in the blood. 
Erythropoietin functions in the recruitment and differentiation of erythroid progenitor cells, 
aids in their maintenance and survival, and stimulates the synthesis of Hb (Ersley, 1991). 
The synthetic Epoetin alfa, the most used administered form of EPO available, is identical to 
endogenous erythropoietin in its amino acid sequence and biologic activity (Figure 2).  
 
Fig. 2. Eprex molecule, a synthetic erythropoietin alpha (pharmaeurope.com) 
Like endogenous erythropoietin, epoetin alfa effectively and safely stimulates synthesis of 
Hb. The medication can best be administered subcutaneously with 4 injections during the 3 
weeks prior to surgery with the last injection given in the operating theater. The 
subcutaneous method is better than the intravenous administration because the slow release 
from the depot provides a more sustained plasma level (Ersley, 1991). The amount  
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of erythropoietin given should be 300 IU/kg/day for 15 days peri-operatively or 600 IU/kg 
in 4 weekly doses beginning 3 weeks prior to surgery (Figure 3). 
 
Fig. 3. Treatment algorithm for the use of Epoitin alpha in anemic patients scheduled for 
elective non-cardiac, non-vascular surgery at high risk for transfusion because of anticipated 
blood loss (Keating & Meding, 2002). 
Erythropoietin should be used in combination with oral or intravenous iron administration 
to boost the erythrocyte production (García et al., 2009). If erythropoietin is used allogeneic 
transfusions are markedly reduced. In a prospective observational study of low Hb patients 
to whom 600 IU/kg EPO in 4 doses was administered, a transfusion percentage of 3.6% was 
found, while in the low Hb group who did not receive EPO the percentage was 45.2%, and 
in the normal Hb group 11.9% (Lafosse et al., 2010). The reduction of allogeneic transfusions 
reached with the administration of EPO was therefore 92% (Lafosse et al., 2010). 
Epoietin alfa is expensive but very effective in increasing the Hemoglobin level of the 
patients by 4g/dl in 4 weeks (if administered 600 IU in 4 subcutaneous injections) which is 
equivalent to 5 units Red Blood Cells. The Canadian Coordinating Office for Health 
Technology Assessment performed an economic evaluation of erythropoietin use in surgery 
in 1998. In their report they state the costs of EPO to be less than 100,000 dollars per gained 
life year. Assuming 10% of all hip arthroplasty and cardiac bypass surgery patients need 
EPO they calculated the total costs for the Canadian health care to be 5.9 million dollars 
annually. These costs were to be made in order to have a potential benefit of 0.12 life years 
gained for the total population (Otten, 1998). If, however, the use of EPO and autologous 
transfusion are compared to pre-donation, EPO has better results in the increase of Hb and 
decrease of allogeneic transfusions (Deutsch, 2006). 
4. Peroperative measures 
In orthopaedic surgery multiple options are available to help reduce the intra-operative 
need for allogeneic blood transfusion. Although some methods are very commonly used 
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worldwide, other methods are used less frequently. In this section we will discuss a 
selection of the major methods in the current orthopedic practice, divided into surgical and 
anaesthesiological techniques, autologous blood transfusion and anti-fibronolytic drugs.  
4.1 Surgical and anaesthesiological techniques 
During operation surgical haemostasis should be performed as thoroughly as possible. In 
orthopedic surgery electrocautery is the most widely used technique. Operations can be 
performed using a tourniquet and exsanguination to reduce the amount of shed blood. If, and 
wherever possible, the use of endoscopic techniques can help to reduce the amount of shed 
blood. The use of anesthesiological techniques such as controlled hypotension, maintenance of 
normothermia and acute normovolemic dilution can reduce the loss of blood as well.  
The usage of tourniquets in total knee arthroplasties is often used to help reduce the intra-
operative blood loss (Matziolis et al., 2011; Smith & Hing, 2010; Zhang et al., 2010). Matziolis 
et. al. found this to be an effective method to reduce intra-operative blood loss (Matziolis et 
al., 2011). A study by Zhang et. al. found a decrease in  intra-operative blood loss, but also a 
significant increase in post-operative blood loss (Zhang et al., 2010). A systematic review 
and meta-analysis by Smith and Hing found a significantly reduced level of intra-operative 
blood loss in patient groups where tourniquets were used, compared to non-tourniquet 
control groups. They state however, that there was no difference found in total blood loss 
and complications were more frequent in the tourniquet groups (Smith & Hing, 2010). The 
usage of tourniquets seems to reduce the amount of blood loss intra-operatively, but it 
increases the amount of post-operative blood loss. It is therefore useful to take proper post-
operative measures, e.g. the use of post-operative autologous reinfusion systems or 
tranexamic acid. These methods will be discussed later in this chapter. 
When using acute normovolemic dilution, patient’s blood is withdrawn intra-operatively or 
shortly before the operation. The withdrawn blood is replaced by an equal volume of 
crystalloid or colloid solution. In normal circumstances 0,5-1,5 liters of blood are withdrawn 
from the patients circulation. This  makes the blood lost contain less erythrocytes, making 
the loss of blood less important. The withdrawn blood is always re-transfused as autologous 
transfusion. Davies et. al. compared different studies and concluded that acute 
normovolemic dilution may be a cost effective method to decrease the need for allogeneic 
blood transfusion (Davies et al., 2006). Goodnough et. al. compared the methods of pre-
operative autologous blood donation and acute normovolemic hemodilution in patients 
undergoing total hip arthroplasties. They found acute normovolemic hemodilution to be 
safe. No differences were found regarding the need for allogeneic blood transfusion in both 
groups. However, acute normovolemic hemodilution turned out to be significantly more 
cost effective than pre-operative autologous blood donation (Goodnough et al., 2000). 
4.2 Autologous transfusion 
The option of intra-operative autologous transfusion is interesting because of the theoretical 
possibility for re-infusion of infinite amounts of blood. The use of autologous transfusion in 
orthopedic surgery is useful in large surgeries, i.e. spine and revision surgery, though not in 
infections and tumor surgeries. Autologous transfusion in smaller surgeries is not practical 
and expensive.  
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4.2.1 Washed autologous transfusion  
For over 30 years the method of washed autologous transfusion has been used successfully  
in multiple medical disciplines, especially in surgeries with expected major blood loss. The 
use of cell saving techniques is warranted to accomplish this. Herein the shed red cells are 
collected, washed, concentrated and re-infused into the patient. As stated before, the 
potency of re-infusing large amounts of blood is a great advantage of the cell savers. In 
orthopedic surgery however, the loss of blood intra- and post-operatively rarely approaches 
the huge amounts of blood loss in, for instance, cardiac or trauma surgery. In other words, 
the role of cell saving in orthopedic surgery is limited.  
Carless et. al. conclude in their systemic review that cell salvage is an effective tool to reduce 
the need for allogeneic blood transfusion in both cardiac and orthopaedic surgery. They 
state however that many studies may have been biased and are therefore difficult to 
interpret (Carless et al., 2010). It is stated that intra-operative cell salvage is beneficial in 
surgery when blood loss exceeds 1,000 ml (Lemaire, 2008; Sculco, 1995). Davies et. al. find 
that cell salvage may be cost effective (Davies et al., 2006). However, it should again be 
noted that many studies may not be reliable due to biasing.  
In their study, Benli IT et al. found higher hematocrit level in patient´s blood when cell 
salvage was used intra-operatively compared to a control group (Benli et al., 1999). Usage of 
intra-operative cell salvage also provides advantages regarding post-operative wound 
infections and the healing process of the wound (Duffy & Neal, 1996; Steinitz et al., 2001; 
Weber et al., 2005 ). 
The use of allogeneic blood transfusion comes with an increased risk of post-operative 
wound infections as is shown in two studies (Duffy & Neal, 1996; Steinitz et al., 2001). Duffy 
finds a decrease in post-operative wound infections when autologous blood is used for 
transfusion instead of allogeneic blood (Duffy & Neal, 1996). Also, the post-operative 
wound healing may be positively  influenced by using cell salvage, as Weber et. al. find a 
longer healing process after usage of allogeneic blood transfusion, compared to a control 
group in which patients did not receive allogeneic blood transfusion (Weber et al., 2005).   
The normal way to collect shed blood is using a vacuum suction device. Many studies have 
been done to identify the best ways of collecting, especially regarding vacuum suction 
pressure and blood-air contact. Gregoretti found in his study that a vacuum pressure of up 
to 300 mmHg could be used safely, considering that the levels of potassium, hematocrit and 
red blood cells did not change significantly when higher pressures than normal (above 150 
mmHg) were used (Gregoretti, 1996). He did find however substantial influence of the air-
blood contact on the level of hemolysis. A study by Waters et. al. showed that hemolysis 
increased when a higher vacuum pressure was used in the suction device. Furthermore, 
they found that suction from flat surfaces also increased the level of hemolysis, when 
compared to suctioning from a cavity (Waters et al., 2007). They advise diluting the blood 
with normal saline while it is collected, using minimal vacuum pressure and minimizing the 
contact between the collected blood and air, both in the suction tube as well as in the 
collecting device, for this too will increase the amount of hemolysis, thus reducing the 
quality of the blood. In another study Yazer et al. also conclude that a higher level of air-
blood contact increases the level of hemolysis. They also found that hemolysis was 
decreased by using a vacuum suction device with variable pressure (Yazer et al., 2008).  
www.intechopen.com
 
Blood Transfusion in Clinical Practice 
 
68
Another interesting point of debate in cell salvage is the use of it in revision of metal on 
metal (MoM) hip prosthesis revisions which is increasingly problematic at present in 
orthopedic surgery. The MoM prostheses, which gained in popularity the past years, have 
lately proven to shed a lot of metal ions which induce increased levels of mainly Cobalt and 
Chromium ions in the plasma and full blood of patients and local pseudotumors consisting 
of large amounts of metal ions in granulomatous tissue surrounding the prostheses causing 
loosening. If those prostheses are to be revised the metal ions are likely to be sucked into the 
cell saver with the blood and the plasma components. The metal ions are mostly solved in 
plasma and incorporated in the leucocytes and thus reintroduced into the patient with the 
red cells and the leucocytes at retransfusion. Since these ions are known to be carcinogenic 
and tend to accumulate in the liver, the spleen, the kidneys and the lymphatic system the 
extra amount of these metal ions introduced in the patients circulation at re-transfusion of 
the salvaged blood during operation might increase the risk for serious long term 
complications. The effects of these metals have not been investigated properly since they 
have not been used in large quantities for long enough to induce carcinomas but the extra 
load of the ions which is potentially introduced during revision surgery has, potentially,  
such hazardous  consequences that we think we should advise against using cell salvage in 
the presence of MoM  prostheses. More research on this subject is desired. 
4.2.2 Non-washed autologous transfusion 
Using non-washed blood is a relatively new way to achieve reduction of allogeneic blood 
transfusion. In this method, shed blood is collected intra-operatively and is to be re-infused 
into the patients circulation after a filtration process. One has to consider that unwashed 
intra-operative autologous transfusion differs from the post-operative autologous 
transfusion, the method we will discuss in the next subsection of this chapter. While 
collecting the shed blood intra-operatively, large amounts of lipids and bone marrow will 
also be aspirated into the collecting device. This collateral catch may obstruct the filters of 
the device, ultimately blocking the system.  
The lipids, if not properly filtered, can potentially increase the risk of fatty embolism if 
introduced in the circulation. The risks of these fatty embolisms have been described 
extensively in the literature concerning cemented hip prostheses as they are widespread 
during the preparation of the bone for the prosthesis.  
Then there is the theoretical possibility to be considered of tiny bone fragments collected 
from the surgical wound to rupture the filter in the device or even cause vessel ruptures 
after being re-infused into the patient’s circulation. However, the latter has never been 
described so far and is very difficult to prove.  
The use of non-washed blood from the wound is still under investigation and debate. In 
three different studies, blood samples are tested after being filtered and considered to be 
safe when reinfused, regarding potassium, sodium, plasma haemoglobin and systemic 
haemoglobin levels (Bengtsson et al., 2008; Kvarnström et al., 2008; Stachura et al., 2008). 
Wiekenkamp et. al. however question the safety of this particular device as they found high 
levels of plasma haemoglobin (>0.64 g/dl) in their blood samples after filtration 
(Wiekenkamp et al., 2010). These levels are comparable with levels found by Kvarnström et. 
al. and Bengtsson et. al., 1.15 g/dl and 1.63 g/dl respectively. Wiekenkamp et. al. continue 
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with an example by stating: a normal person is physically capable to bind 0.03-0.2 g/dl of 
plasma haemoglobine to haptoglobine. Considering one has the capability to bind 0.2 g/dl 
and a circulating blood volume of six liters, a maximum of 12.0 g of plasma haemoglobin 
can be bound. Higher plasma haemoglobin levels will result in saturation of haptoglobine 
and the risk of binding of plasma haemoglobin to nitric oxide, which will result in 
dangerous reactive oxide radicals. In this case the maximum level of plasma haemoglobin to 
safely re-infuse 500 ml of filtered blood, is 2.4 g/dl. Considering that many patients have 
less binding capabilities, the risk of saturating haptoglobine and therefore endangering the 
patient with reactive oxide radicals is very real (Wiekenkamp et al., 2010). 
4.3 Anti-fibronolytic drugs 
The use of medical agents, like tranexamic acid, can be a useful tool to reduce blood loss 
preoperatively (Erstad 2001a; Erstad 2001b; Henry et al., 2011; Keating, 1999; Lemaire, 2008;  
Sepah et al., 2011).  Anti-fibronolytic drugs are to be given pre-, intra- or post-operatively, 
depending on the kind of drug that is used. Purpose of using these anti-fibrinolytic agents is 
decreasing the volume of intra- and post-operative blood loss. Because of the relatively low 
costs and their successful use in many disciplines, e.g. gynaecology and cardiac surgery, the 
anti-fibrinolytic drugs are an interesting option in orthopedic surgery.  
Henry et. al. found a decrease in blood loss and a lower need for allogeneic red cell 
transfusion when anti-fibrinolytic drugs were used. Aprotinin showed slightly better results 
than tranexamic acid or epsilon aminocaproic acid in comparative studies, but also a higher 
risk of death. No serious adverse effects were found while using tranexamic acid or epsilon 
aminocaproic acid (Henry et al., 2011). In a retrospective study comparing a group of 
patients who received tranexamic acid pre- or post-operatively to a group of patients who 
did not receive tranexamic acid,  Sepah et. al. found a significant effect of tranexamic acid. 
Both the value of the mean Hb-loss and the mean volume of post-operative wound drainage 
had  substantially decreased in the group of patients who received tranexamic acid (Sepah et 
al., 2011). Den Hartog et. al. compared a group of patients who did receive tranexamic acid 
intra-operatively with a control group in both total knee and in total hip surgery. In the total 
knee surgery a 55.6% decrease of blood loss was found post-operatively. In total hip surgery 
they found a decrease of 20.4%( den Hartog & Roorda, 2011).  
In three studies no increased incidence of deep vein thrombosis was found when tranexamic 
acid is given to patients during total knee replacements (Nielsen & Husted, 2002; Orpen et 
al., 2006; Zhang et al., 2007). According to Nielsen, the optimal effect is reached by starting 
with a bolus of 10-15 mg/kg. There seems to be less effect in every dose given on top of the 
initial dose (Nielsen & Husted, 2002). The three afore mentioned studies conclude that the 
use of tranexamic acid in total knee replacements is an effective way to reduce post-
operative blood loss. Camarasa et. al. find the decrease in blood loss reflected in a reduced 
requirement for allogeneic blood transfusions (Camarasa et al., 2006). In a study by Good et. 
al. a decrease in total blood loss was also found when using tranexamic acid in total knee 
replacements. They state however that the concealed blood loss was not that much 
influenced when tranexamic acid was used (Good et al., 2003). 
In a meta-analysis and systemic review by Sukeik et. al., use of tranexamic acid in patients 
undergoing total hip replacements was studied. According to Sukeik the use of tranexamic 
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acid reduces the requirement for allogeneic blood transfusion. Furthermore, no significant 
differences were found between control groups and groups in which tranexamic acid was 
given, concerning adverse events, such as infection rates or deep vein thrombosis (Sukeik et 
al., 2011).  
Ortega-Andreu et. al. compared a group of patients who received tranexamic acid intra-
operatively to a control group, consisting of historical patients who had not received 
tranexamic acid. The tranexamic acid group showed a decrease in allogeneic transfusion 
rate, lower visible blood loss and proved to be more cost effective than the control group 
(Ortega-Andreu et al., 2011). 
Given the relatively low costs , the effectiveness and the slight chance of adverse events, it 
can be stated that usage of tranexamic acid is a safe and reliable way of decreasing the need 
for allogeneic blood transfusion. 
5. Postoperative techniques 
Postoperatively it still is possible to reduce further allogeneic transfusion.  
5.1 Re-transfusion of wound drain fluids 
In orthopedic surgery, especially adult reconstruction surgery, such as hip and knee 
replacements, most patients lose about 1-1.5 liters of blood during surgery if it is not 
performed using a tourniquet. Especially in knee surgery the tourniquet can, as previously 
described, reduce the preoperative bloodloss substantially. If a tourniquet has been used, 
the patient will still lose some 1-1.5 liter blood from the wound but using postoperative 
collection techniques this blood can be returned to the patient and thus reduce further 
allogeneic blood transfusion.  In hip surgery the use of a tourniquet is, of course, not 
possible so the amount of blood, shed during surgery, is higher and the use of drainage 
fluids to return to the patients is more arguable.  
At the end of the operation wound drains may be left behind in the wound to reduce 
swelling and hematoma formation. The fluid from these drains can be collected and, after 
filtration, be re-infused to the patient (Hendriks et al., 2009). We conducted several studies 
concerning the use of these drains and their safety. If such a system is to be used the first 
choice to be made is the type of system one wants to use. Several types of systems are 
marketed. The main difference between them is the application of continuous vacuum or 
intermittent vacuum using a bellow system. A second difference between systems is the 
filter used to reduce the amount of leucocytes and thrombi. Most systems use standard 
Sangopur® filters which is a gradual screen filter with pore size of 80 and 40 microns. Some 
systems use a Pall Lipiguard® Filter, which is a depth filter consisting of polyester screen 
media with variable pore size with the smallest size being 40 microns. A third difference is 
the vacuum pressure reached. In the bellow systems the maximum vacuum pressure 
reached is 90 mmHg, whereas in the continuous vacuum systems the vacuum pressure can 
be as high as 150 mmHg. 
The numerous differences between the systems make comparison difficult and give rise to 
continuous debate.   
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5.1.1 Vacuum type and pressure 
The vacuum type and especially the vacuum pressure has been the subject of debate 
between producers. It has not been proven one or the other is better. The erythrocytes seem 
to be able to survive equally well in 90 as in 150 mmHg vacuum. If the vacuum were a 
problem at higher values the erythrocytes would burst and thus the plasma hemoglobin 
would be raised in comparison to low vacuum systems. This seems not to be the case if 
blood is suctioned from containers (Waters et al., 2007). If suctioned from a flat surface the 
vacuum pressure does make a difference though it is very small (Yazer et al., 2008). 
‘Although the variable-pressure device produced a significant reduction in hemolysis 
during one-pass blood collection, the clinical significance of this reduction is not clear. In 
relative terms, the variable-pressure device would recover an extra 10 ml of RBCs for every 
liter of salvaged RBCs, which is negligible compared to the blood loss in major surgery.’ The 
drains used in wound drainage, however, do not suck the blood from a flat surface, but 
from a cavity, more like the cups used in Water’s study previously mentioned. Since the 
vacuum pressure does not seem to matter if the blood is taken from a cavity the activity of 
the vacuum on the wound healing as such might be taken into account.  
The type of vacuum used has proven differences if the effects on wound healing are 
compared. Berman et al. proved that 80% of the total drainage is collected within 6 hours 
post-operatively with a constant suction device, whereas with intermittent suction this is 
spread over days (Berman et al, 1990). Furthermore they state that a clear advantage to 
using a continuous vacuum suction device over an intermittent spring-loaded device is seen 
with respect to hematoma evacuation, wound drainage, wound healing, and possible 
complications. 
There are no proper studies addressing the differences between continuous and intermittent 
suction in re-transfusion drain models. 
5.1.2 Filter type 
One point that needs addressing if we speak about filter type is whether or not leucocytes 
from the wound are to be re-transfused into the patient. Especially in cardiac surgery 
patients who need more than three blood transfusions, leukocyte depletion by filtration of 
the allogeneic blood, results in a significant reduction of the postoperative mortality. This 
effect can only partially be explained by the higher incidence of postoperative infections 
in those receiving packed cells without buffy coat (van de Watering et al., 1998). Some 
researchers believe the activated leucocytes do no harm, might even improve wound 
healing by triggering the body to a generalized activated state of inflammation, thus 
reducing the amount of infections (Innerhofer et al., 2005). The leucocytes activated in the 
study of Innerhofer, however, were activated by contact with foreign surfaces, not by the 
wound itself for he used pre-donated autologous blood and compared that to allogeneic 
blood. Others believe thus activated leucocytes induce a generalized activation of the 
immune system which reduces lung function and increases the inflammatory response of 
the body (Gu et al., 1996). Especially in cardiac surgery the effects of extracorporeal 
circulation have been extensively investigated. Contact of blood with foreign surfaces, as 
in the containers of the retransfusion systems, activates complement and leucocytes 
(Kirklin, 1991), as does the suction of the blood from the surgical wound (Bengtsson & 
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Lisander, 1990; Sieunarine et al., 1991). Washing the blood, which is done in intra-
operative cell salvage, does reduce the complement complexes but in the postoperative 
systems in which the blood is not washed but only filtered, these activated complement 
complexes pass some of the filters used. Moonen et al described that filters do have an 
influence on the quality of retransfused blood. The Pall® filter reduced the amount of 
leucocytes and thrombocytes more adequate then the Sangopur® filter with the latter 
allowing more erythrocytes to pass (Moonen et al., 2008). The thrombocytes found in the 
transfused blood using the Sangopur filter® are, since they are not found with use of the 
Pall® filter and both  filters are 40 microns large, likely to be thrombi and not loose 
thrombocytes. This might mean that the activated complement complexes, being 
incorporated in the thrombi, pass the Sangopur® filter, thus activating the body’s 
inflammatory response. Some studies investigating the general reactions of the body to 
retransfused blood found no transfusion reactions nor fevers when transfused with 
unwashed, filtered autologous blood. Some chills were found, though (up to 3,1%), with 
use of a non-leucocyte depleting filter (Athanasoulias et al., 2007; Horstmann et al., 2010). 
Duchow et al found high levels of factor XIIa, thrombin and fibrin generation markers, 
and markers of fibrinolysis in the shed blood. After re-transfusion increased levels of 
these markers together with decreased values for factor XIII and plasminogen were found 
in the circulation indicative of renewed clot formation and fibrinolysis. These changes 
were highly significant compared to pre-re-transfusion values of the patient’s blood. The 
unwashed drainage blood contained high levels of pro-coagulation material and induced 
an activation of the plasma coagulation pathway with renewed clot formation and 
fibrinolysis in the patients (Duchow et al., 2001). De Jong et al found similar results as 
they found markedly increased activation of leucocytes and platelets and a distinctive 
decrease in platelet count of the recipient after infusion, thus potentially favoring 
thrombosis (de Jong, 2007). 
 
 
 
 
Fig. 4. The Sarstedt retransfusion system 
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Fig. 5. The Bellovac ABT system 
 
 
Fig. 6. The Donor system 
5.1.3 Total system comparison 
No published studies have been done comparing different draining systems for re-
transfusion of drain fluids. In a study comparing three systems in a total of 80 patients with 
52 hip and 28 knee arthroplaties, a system sold by Sarstedt® (28 patients), which is a bellow 
system using a stepwise filter of 120 to 10 microns, one from Astra Tech (Bellovac ABT®)(24 
patiets), which uses a bellow system and a Sangopur® filter and one from van Straten 
Medical (Donor®)(28 patients) with a Pall Lipiguard® filter, we tested the Hb, leucocytes, 
complement C5 and antithrombin 3 (AT3). In the final samples, just before infusing the 
blood into the patients the measurings were done. Patient characteristics were comparable, 
and a mean of 484 ml (150-1300 ml) drain fluid was collected. No differences between the 
systems regarding the amount of drain fluids collected were found. Table 1 shows our 
findings. 
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Sarstedt Bellovac Donor 
Hb (g/dl) 8.86 11.28 11.44
Leucocytes (x109/l) 3.8 3.4 0.5*
C5 (IE/ml) 78.7 87.7 80.6
AT3 (% of normal) 31.8* 41 37.5
Table 1. Blood component concentrations in the retransfusable blood in the different 
systems. (*p<0.05) 
As the table shows the levels of AT 3 are substantially lower than normal in blood (0.12 
mg/ml), while the levels of C5 are normal and the Hb levels are low. The leucocytes are 
adequately filtered by the Pall® filter. AT 3 is known to be low after major surgery. Obviously 
the complement has not been used to activate clotting, not even in the Donor® system which is 
the only system without heparin coating in the container (van den Boom & van Erve, non 
published data). The quality of the blood collected in the three systems seems to be comparable 
although the systems do have different collection mechanisms, (two bellows and one 
continuous vacuum), different suction pressures (Sarstedt® 70 mmHg, Bellovac ABT® 90 
mmHg and Donor® 150 mmHg) and also different filter systems, as previously described.  
The choice of system seems to be led by the wish of the physician in attendance to donate 
the leucocytes and the thrombi back into the patient. Since that is not adequately proven to 
be good or bad, as mentioned earlier,  it remains the choice of the orthopedic surgeon. 
5.1.4 Effects of the introduction of re-transfusion of drainage fluid in orthopedic surgery 
To determine whether or not the introduction of re-tansfusion of drainage fluid is worthwhile 
we did a prospective observational study (Hendriks et al., 2009). We compared 195 patients 
before introduction of the re-transfusion system in our hospital to 175 patients after the 
introduction of the device. We used the Donor® type drain as described earlier. A restrictive 
transfusion trigger was used for all patients and patients with a preoperative  Hb lower than 
13.2 g/dl received EPO (4 doses of 600 IU each). All patients were treated with Acenocoumarol 
to prevent thrombosis starting the day of surgery (INR targetlevel: 2.5-3.4). Hip and knee 
arthroplasty patients were evenly distributed between groups as were the other patient 
characteristics (Table 2). The use of re-transfusion of drainage fluid reduces the use of 
allogeneic transfusions by 70-98% depending on the type of surgery and the system used.  
 
 Total hip arthoplasty Total knee arthroplasty  
 
No autotra-
nsfusion
Autotra-
nsfusion
p 
value
No autotra-
nsfusion
autotra-
nsfusion 
p 
value 
Nr of patients 128 100 67 68  
Male (n/%) 37 (29) 34 (34) 0.41 17 (25) 15 (22) 0.65 
Mean age (range) 70.5 (39-95) 69 (46-90) 0.20 71.5 (38-91) 73.7 (53-93) 0.16 
Mean nr RBC’s (range) 0.4 (0-4) 0.06 (0-2) <0.01 0.8 (0-6) 0.02 (0-1) <0.01 
Mean volume 
autotransfusion in ml 
(range) 
 409 (0-750)   505(0-1000)  
Table 2. patient characteristics and results of a study into the effects of introductions of an 
autotransfusion system on the need for allogeneic transfusions in hip and knee arthroplasty 
patients. (RBC = unit allogeneic blood, p  is calculated using χ2 or t-test) 
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In a logistic regression analysis in this study the only factor of interest proved to be the use 
of autologous transfusion. 
5.2 Use of a restrictive transfusion trigger 
Another important measure to be taken after the operation is the use of a restrictive 
transfusion trigger. This means that the patient should not be given blood unless the oxygen 
transport capacity is proven to be lower than the tolerable threshold. The University of 
Groningen together with the CBO (Centraal Begeleidings Orgaan, Dutch for Central 
Counseling Bureau) developed a guideline for transfusion which is widely used throughout 
The Netherlands. It is called 4-5-6 rule (the Hb is expressed in mmol/l in The Netherlands) 
the international formulation would be: 6.5-8-9.7 rule. The rule is adopted by the national 
Bloodbank, Sanquin®, and put forward in their transfusion manual (van Rhenen et al., 2011).  
This rule uses the ASA class (system developed by the American Society of 
Anethesiologists) as a guideline to the patient’s general health. The ASA class defines the 
general condition of the patient’s health and is used by anesthesiologists worldwide to 
assess in easy terms the preoperative condition of the patient. 
 
Consider transfusion if the Hb < 6.5 g/dl (Ht: 0,20) and if there is : 
acute blood loss in healthyindividuals (ASA-class I) < 60 years old with 
normovolemia and blood loss in 1 location 
chronic asymptomatic anemia. 
 
Consider transfusion if the Hb < 8 g/dl (Ht: 0,25) and if there is: 
acute blood loss in healthyindividuals (ASA-klasse I) ≥ 60 years old with 
normovolemia and blood loss in1 location 
acute blood loss in healthy individuals < 60 years old with normovolemia and 
blood loss at more than 1 location (polytraumapatients) 
expected  blood loss > 500 ml in a patient < 60 years old who will be operated 
upon 
fever 
uncomplicated post-operative period after open heart surgery 
uncomplicated ASA-class II en III 
 
Consider transfusion if the Hb < 9.7 g/dl (Ht: 0,30) and if there is: 
ASA-class IV 
Inability to increase heart minute volume to compensate for 
haemodilution 
sepsis or toxinemia 
serious lungdisease 
symptomatic cerebrovascular disease 
 
Formulated by: University Medical Centre Groningen.  
Source: www.cbo.nl/product/richtlijnen/folder20021023121843/bloedkaart.pdf 
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The 4-5-6 rule is an easy to use guide to whether or not transfuse patients based on their 
capacity to cope with anemia. Several studies showed that postoperative anemia is generally 
well tolerated as it is in the critically ill. Post-operative anemia after cardiac operations, with 
hemoglobin levels of 8 to 10 g/dl is well tolerated in patients who have not received a 
transfusion and induces only a transient impairment of exercise tolerance (Ranucci et al., 
2011). Moreover, in critically ill patients a restrictive transfusion trigger is well tolerated 
(Nichol, 2008) as it is in critically ill children (Lacroix, 2007). The rule of thumb as 
formulated by the University of Groningen and accepted by the Dutch National Bloodbank 
and the counseling bureau has proven right in even the critically ill.  
For the international community one could consider to change the lower limits from 6.5, 8 
and 9.7 to 7, 8 and 10 to make it easier to remember, which is one of the prerequisites for a 
good rule while still being safe. The limits are thus a little higher than needed, but are 
comprehensive, easy to remember, easy to use and proven safe. It saves a little less blood 
than with the limits set more restrictive but the easy application makes the rules more 
widely acceptable and introducible.  
6. Conclusion 
In orthopedic surgery, as in other surgeries and in the critically ill, the use of allogeneic 
blood can be reduced using a wide variety of methods and techniques. All those different 
methods individually have proven to contribute to the reduction of the use of bank blood. 
Few if any studies have been done to find out what the combined effect of the introduction 
of the different methods is. Generally it is assumed the methods and techniques reinforce 
each other. The additive effect of the used methods is, however, not clear. 
The costs of the combination of blood saving methods may, in the end, outweigh the costs of 
allogeneic blood. It is, however, very difficult to determine the costs of allogeneic blood. In 
addition to that, the costs are different for every country because of the difference in blood 
bank systems, salaries and overhead costs.  
The effect of hospital admission time has been made clear by Weber et al. who described an 
increase of hospital admission time of 2.7 days (+/- 0.5 days) per transfused unit of red 
blood cells in total hip arthroplasty patients(Weber et al., 2005). In a study we performed in 
1,422 patients who received a total hip arthroplasty, we found the administration of 
allogeneic blood to be one of the independent variables in a stepwise regression analysis, for 
ASA-Classes: 
I: healthy individuals; 
II: patients with a mild systemic defect, without functional impairment; 
III: patients with a seriously impairing systemic defect; 
IV: patients with a systemic defect that poses a constant threat for life; 
V: patients who are moribund and who will, with or without operation, probably 
die within 24 hours. 
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hospital admission time, increasing admission time by 1.78 days per unit Packed cells 
(p<0.000) (van Erve et al., 2010). 
All in all it seems appropriate for all of the above-mentioned measures to be combined to 
reach the goal set, which is to reduce the administration of allogeneic blood to the 
minimum.  
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